Compare · CDXC vs VGR
CDXC vs VGR
Side-by-side comparison of ChromaDex Corporation (CDXC) and Vector Group Ltd. (VGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXC and VGR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- VGR is the larger of the two at $1.74B, about 9.8x CDXC ($176.9M).
- CDXC has more recent analyst coverage (5 ratings vs 4 for VGR).
- Company
- ChromaDex Corporation
- Vector Group Ltd.
- Price
- $7.87-0.76%
- $14.99+0.20%
- Market cap
- $176.9M
- $1.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 4
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Vector Group Ltd.
Vector Group Ltd., through its subsidiaries, manufactures and sells cigarettes in the United States. It operates in two segments, Tobacco and Real Estate. The company produces cigarettes in 100 combinations under the EAGLE 20's, Pyramid, Montego, Grand Prix, Liggett Select, Eve, and USA brand names, as well as various partner and private label brands. In addition, it provides residential real estate brokerage, relocation, real estate sales and marketing, and title insurance services to real estate buyers and financial institutions; manages cooperative apartment buildings, condominium apartment buildings, and rental apartment buildings; and invests in, acquires, and owns real estate properties or projects, as well as develops land. Further, the company operates elliman.com, a website that enables consumers to search properties and access current market information, as well as offers building and neighborhood guides, and other interactive content. It markets and sells its cigarettes to wholesalers and distributors of tobacco and convenience products, as well as grocery, drug, and convenience store chains. The company was formerly known as Brooke Group Ltd. and changed its name to Vector Group Ltd. in May 2000. Vector Group Ltd. was founded in 1873 and is based in Miami, Florida.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
Latest VGR
- SEC Form 15-12G filed by Vector Group Ltd.
- Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.